A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)

Phase 2

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease (COPD)

• Registration Number: NCT00392587
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-08
• Study First Submitted: 2006-10-24
• Study First Submitted QC: 2006-10-25
• Study First Posted: 2006-10-26
• Status Verified: 2011-03
• Last Update Submitted: 2012-05-31
• Last Update Posted: 2012-06-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Measurements of adverse events, changes in heart rate, blood pressure, blood tests, heart function and lung function throughout the 14 day study. Exacerbations of COPD over the 14 day study.	14 days

Secondary Outcome Measures

Name	Time	Method
Concentration of the drug in the blood after 1, 3, 7, 10 and 14 days of dosing.	after 1, 3, 7, 10 and 14 days of dosing
Inhibition of inflammatory agents in the blood after 7 and 14 days of dosing.	after 7 and 14 days of dosing

Trial Locations

Locations (1)

GSK Investigational Site; 🇩🇪 Berlin, Germany